Zenith Epigenetics Ltdis A Clinical Stage Biotechnology Company Based In Calgaryalbertacanadathe Company Specializes In Developing Innovative Therapeuticsparticularly Bromodomain And Extra Terminal Inhibitorsbeti Aimed At Treating Various Cancers And Other Disorders With Significant Unmet Medical Needszenith Epigenetics Is Focused On Translating Bromodomain Biology Into Effectivetargeted Treatments For Patients The Company Is Actively Engaged In Research And Development To Advance Its Pipeline Of Bet Inhibitorsthese Drugs Target Specific Proteins Involved In Gene Expression And Have Shown Promise In Modulating Epigenetic Processes To Treat Cancerzenith Epigenetics Is Committed To Conducting Preclinical And Clinical Trials To Evaluate The Safety And Efficacy Of Its Compoundsthe Company Operates As A Wholly Owned Subsidiary Of Zenith Capital Corp Which Provides Strategic Support For Its Initiatives
